| Bioactivity | CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively[1]. CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease[2]. | |||||||||
| Invitro | CUDA (10 μM; 18 hours) produces 6- and 3-fold increases of PPARalpha in COS-7 cells[2].CUDA does not alter PPARalpha protein expression, and it competitively inhibits the binding of Wy-14643 (pirinixic acid) to the ligand binding domain of PPARalpha, suggesting that it functions as a PPARalpha ligand[2]. Western Blot Analysis[2] Cell Line: | |||||||||
| Name | CUDA | |||||||||
| CAS | 479413-68-8 | |||||||||
| Formula | C19H36N2O3 | |||||||||
| Molar Mass | 340.50 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Morisseau C, et al. Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol. 2002 May 1;63(9):1599-608. [2]. Fang X, et al. Activation of peroxisome proliferator-activated receptor alpha by substituted urea-derived soluble epoxide hydrolase inhibitors. J Pharmacol Exp Ther. 2005 Jul;314(1):260-70. |